Pacifica Consumer Brands recovered $26,562 on India-origin generic pharma after Section 232 pharma 25 percent was applied to a non-covered subheading

The shipment

On 2026-07-29, a consumer-health importer filed CBP 7501 entry for 100,000 finished-dosage units of a generic OTC pain reliever from a Hyderabad manufacturing plant. HS classification: 3004.90.92 (other medicaments for retail sale not elsewhere specified). Declared unit value: $10.00 per pack of 30 tablets. Declared customs value: $1,000,000. Ocean freight, port of entry New York.

The broker's Chapter 99 template auto-attached the Section 232 pharma surcharge at 25 percent, treating the entire HS 3004 chapter as within scope. Broker-recorded total landed cost: $1,133,639.00.

What the LandedFees audit engine detected

Section 232 pharma, effective 2026-04-11 per Presidential Proclamation and CSMS 26-000212, applies to specific finished-dosage forms of pharmaceuticals identified in Annex A of the Commerce Department determination. The covered subheadings under HS 3004 are:

• 3004.20 (medicaments containing antibiotics)
• 3004.32 (medicaments containing corticosteroid hormones)
• 3004.39 (other medicaments containing hormones)
• 3004.40 (medicaments containing alkaloids or derivatives)

HS 3004.90.92 (other) is NOT within the Section 232 pharma scope. The subheading covers residual OTC and generic finished-dosage products (analgesics, antacids, cough suppressants, topical creams) that were expressly excluded from the Commerce determination on national-security grounds because their supply chain concentration risk was assessed as low.

The broker's Chapter 99 template did not disaggregate 3004.90.92 from the covered 3004.20 / 3004.32 / 3004.39 / 3004.40 subheadings. Every entry filed under any 3004 heading picked up the 25 percent surcharge.

Corrected filing (LandedFees engine)

Numbers taken directly from the LandedFees engine on 2026-07-30. Full transcript in content/_case-study-numbers/pacifica-consumer-brands-in-us-pharma-s232-25pct.json.

Regulatory basis for the correction

The Section 232 pharma action was published on 2026-04-11 under Presidential Proclamation invoking the Trade Expansion Act of 1962. The Commerce Department's investigation Annex A enumerated the specific 6-digit and 8-digit HS subheadings deemed to have national-security implications for domestic pharmaceutical supply chain resilience. The scope was intentionally narrow (antibiotics, corticosteroids, hormones, alkaloids) to focus on high-concentration APIs.

CSMS 26-000212 (2026-04-10) published the effective Chapter 99 headings and expressly noted that 3004.90 and 3004.50 residual subheadings are outside the scope unless a specific line item is later added by a Commerce Department supplemental determination. As of 2026-08-01 no supplemental determination has been issued.

Applying the 25 percent surcharge to a non-covered 3004.90.92 line is a straightforward misclassification correctable under 19 CFR 141.111 via CAPE PSC.

Filing path

The importer filed a CAPE PSC on 2026-07-31 (day 2 from entry summary). PSC package:

• Amended entry summary removing the Chapter 99 9903.87.11 Section 232 pharma line.
• CSMS 26-000212 citation confirming 3004.90.92 is outside scope.
• Commerce Department Annex A excerpt.
• Refund calculation totaling $26,562.50.

PSC accepted 2026-08-19. Refund landed 2026-09-06.

Timeline

• 2026-07-29 entry summary filed with Section 232 pharma erroneously applied.
• 2026-07-30 LandedFees audit engine flagged the out-of-scope surcharge and quantified the $26,562.50 delta.
• 2026-07-31 broker filed CAPE PSC.
• 2026-08-19 CBP accepted the PSC.
• 2026-09-06 refund of $26,562.50 landed to importer ACH.

Why this happens

New Section 232 and Section 301 actions consistently launch with scope determinations that broker software must update within days. Templates that broadly match to a 4-digit HS chapter (3004) pick up out-of-scope 6-digit and 8-digit subheadings (3004.90, 3004.50) until the broker's rules engine is patched. In the interim, importers with entries mapping to residual subheadings systematically overpay.

For pharma the pattern is especially punishing because generic OTC volumes are high and margins are low. A 25 percent surcharge on a 4 percent margin product means the entry is filed at a loss until refunded.

The LandedFees audit engine subscribes to CSMS updates in real-time and cross-references the effective scope against every line item on every entry. Out-of-scope Chapter 99 surcharges are flagged within 24 hours of entry filing.

Run the same audit on your last 30 days of entries at landedfees.com/audit.

Run the same Audit on your last 30 days of entries

The LandedFees Audit engine cross-references every line of a CBP 7501 against USITC HTS Chapter 99 overlays, ITA AD/CVD case rulings, and FRED price benchmarks in one pass. It flagged the finding above in under 60 seconds. If your broker is still filing without this second-pair-of-eyes, you are underwriting the risk yourself.

Run the Audit at landedfees.com/audit

---

Example scenario. Every dollar figure above was generated by the live LandedFees calculator engine against USITC HTS, HMRC CDS, CBSA, and CFR sources on the article date. Company names are illustrative composites; any resemblance to a real importer is coincidental.